Market Research Logo

ADC Contract Manufacturing Market (3rd Edition), 2018-2030

ADC Contract Manufacturing Market (3rd Edition), 2018-2030

INTRODUCTION
Antibody drug conjugates (ADCs) are one of the most popular classes of targeted therapeutic agents and have captured the attention of both large and small pharmaceutical companies, and academic / research institutions across the world. Fundamentally, these complex biotherapeutic entities represent the combination of the target specificity of an antibody and the cytotoxic potential of a chemotherapy drug; such conjugates are believed to be more efficient and effective in specifically identifying and eliminating cells / pathogens that are associated with disease(s). Since the approval of first ADC (MYLOTARG™) in 2000 and its subsequent withdrawal in the year 2010 , the ADC market has evolved considerably. Presently, there are four approved ADCs in the market: BESPONSA® (2017), MYLOTARG™ (2017, reapproval), KADCYLA® (2013) and ADCETRIS® (2011). In fact, in the last 4-5 years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. This is justified by the fact that currently there are close to 200 unique ADC product candidates in the clinical / preclinical phase of development.

Owing to the fact that these novel conjugates are highly potent toxic molecules, their manufacturing requires elaborate technical capabilities, along with the required expertise and manufacturing acumen related to both biologics and highly potent chemical substances. Specifically, the development of an antibody requires experience in protein engineering, cell line development, bioprocess development and related scale-up techniques. The production of the cytotoxic payloads that are used in ADCs requires specialized manufacturing facilities and equipment, highly contained production environments and experts in advanced synthetic chemistry and purification techniques. In addition, ADC developers require access to state-of-art linker technologies and must possess the ability to carry out the bioconjugation of the antibody to the cytotoxic drug. Due to the aforementioned challenges, stakeholders generally don’t opt for manufacturing ADCs in-house. In fact, some of the leading players in this domain are dependent on contract manufacturers for the supply of one or more components of their ADC product candidates. Although some big pharma companies carry out in-house manufacturing of their ADC products, the trend of outsourcing such operations is likely to flourish in the coming years. This trend is expected to be driven by the several small companies and start-ups that are presently involved in development of ADCs.

SCOPE OF THE REPORT
The “ADC Contract Manufacturing Market (3rd edition), 2018-2030” report offers a comprehensive study of the current scenario and future potential of the contract manufacturing market for ADCs. The study features an in-depth analysis, highlighting the capabilities of contract services providers engaged in this domain. In addition to other elements, the study includes:

An overview of the current status of the market with respect to the players involved in the manufacturing of ADCs. It features information on headquarters, size of the company, the types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operations, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / anaytical development).

Elaborate profiles of the contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.

A comparative analysis of the key contract manufacturers based on various parameters, including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, scale of operation, number of ADC development services offered and number of facilities for conjugation services.

An analysis of the recent investments (since 2012) made in this domain, the proceeds of which were intended to be used for the expansion or establishment of new facilities dedicated to offering ADC related services.

An analysis of the recent collaborations (since 2012) focused on manufacturing of ADCs on the basis of year in which the agreement was signed, type of agreement, key players and the geographical distribution of this activity.

An estimate of the overall ADC manufacturing / bioconjugation capacity (in grams / batch) of contract service providers based on information provided on their respective websites (wherever available) and additional data collated via secondary and primary research. The analysis highlights the distribution of global capacity by size of the company / organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).

An overview of the ADCs that are already approved and those that are under development (clinical and preclinical), featuring information related to their current phase of development (wherever applicable), key target indications, developer company / organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.

A review of the evolution of ADC conjugation technologies, highlighting the various types pf approaches that have been adopted in the past, and the different generations of linkers. It also highlights the competition between contemporary technology platforms.

A comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). It provides details related to the different types of payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, current trial status, phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).

An informed estimate of the annual demand for ADC products (in grams), taking into account commercial, as well as clinical scale requirements, based on parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, featuring a Harvey ball analysis, highlighting the relative impact of each SWOT parameter on the overall ADC contract manufacturing market.

One of the key objectives of this report was to evaluate the current opportunity and the future potential of the ADC contract manufacturing market over the coming decade. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. In addition, we have provided the likely distribution of the market based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody manufacturing, HPAPI / cytotoxic production, conjugation / linker and fill / finish), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Our opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with following stakeholders:
Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals)
Anthony DeBoer (Director, Business Development, Synaffix)
Christian Bailly (Director of CDMO, Pierre Fabre)
Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics)
Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
John Burt (Chief Executive Officer, Abzena)
Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
Mark Wright (Site Head, Piramal Healthcare)
Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
Anonymous (Director, Business Development, Leading CMO)
Anonymous (Chief Executive Officer, Leading CMO)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. The market landscape of ADC contract manufacturers is relatively niche with a limited number of companies presently offering contract services for manufacturing / conjugation of ADC products. Of the total number of stakeholders, close to 15 players claim to be one-stop-shops, providing end-to-end services for all the steps of ADC manufacturing (antibody manufacturing to fill / finish). Examples of such players include (in alphabetical order, no specific selection criteria) Abzena, Cambrex, Catalent Pharma Solutions, Goodwin Biotechnology and MabPlex.

2. Over 80% of ADC contract manufacturers are based in either North America or Europe with facilities dedicated to ADC manufacturing / conjugation located in one or multiple regions. Around 50% of the CMOs are large companies with more than 500 employees; examples of such players include (in alphabetical order, no specific selection criteria) Novasep, Pierre Fabre, and WuXi Biologics.

3. Contract manufacturers have made significant investments in expanding their respective capabilities and working capacities in order to address the growing demand for such services. Certain companies have also established new facilities dedicated to bioconjugation and / or manufacturing of highly potent / cytotoxic compounds. Over 60 of such developments were reported during the period 2012-H1 2018; of these, 65% of the instances were facility expansion project (focused on increasing facility area, and adding new manufacturing instruments and fill / finish lines).

4. Close to 80 ADCs are currently in the clinical stages of development. These candidates have been / are being evaluated in more than 400 clinical studies, with over 70,000 patients across the globe. A significant proportion of the current demand for ADC manufacturing (both in-house and outsourced) services is also driven by the four commercially available products. Our estimates (based on parameters, such as target patient population and treatment regimen) suggest that the annual demand for ADCs (in grams) is likely to increase as more late-stage product candidates (phase II and above) receive regulatory approval over the coming decade. Currently, products being evaluated in clinical trials are estimated to contribute around 35% of the annual demand. Our projections indicate that, by 2030, commercialized products are likely to contribute to 90% of the demand for ADC manufacturing services.

5. With a limited number of players offering conjugation / ADC manufacturing services at the commercial scale, the combined global installed capacity available for manufacturing ADCs is estimated to be around 20-30 kgs. It is worth mentioning that a major share (over 90%) of the capacity is installed in facilities of mid-large CMOs, such as BSP Pharmaceuticals, Lonza, Merck / SAFC and Piramal Pharma Solutions. Around 55% of the global ADC manufacturing capacity is installed in facilities based in Europe. This is attributed to the large number of bioconjugation facilities that are presently situated in this region.

6. Driven by the rapidly evolving pipeline of ADC therapeutics and owing to the complex manufacturing requirements of such products, the trend of outsourcing is likely to persist in the foreseen future. Overall, we expect the market to grow at an annualized rate of around 12.1% during the period 2018-2030. Contract manufacturing services for antibodies (for use in ADC production) (~50%) is currently responsible for generating the major share of revenues in this market, followed by conjugation and fill / finish services.

7. In terms of payload types, the demand for services related to manufacturing auristatin and maytansinoid based ADC therapeutics is high and estimated to contribute significantly (~75%) to the market’s revenues. However, the share of PBD based products is expected to grow at a relatively higher annualized rate of over 30% during the forecast period.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market may evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market over the period 2018-2030, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high level view on the likely evolution of the ADC contract manufacturing market in the mid to long term.

Chapter 3 is a general introduction to ADCs and the manufacturing requirements of such therapeutic products. It includes a detailed discussion on the structure of an ADC and its various components, manufacturing steps and associated challenges. The chapter also provides an overview of the growing trend of contract manufacturing, along with the challenges associated with supply chain and the growing demand for one-stop-shops. Further, it features a discussion on the various parameters that a sponsor company needs to consider while selecting a contract manufacturing partner.

Chapter 4 provides a comprehensive overview of contract manufacturers that are actively involved in the production or conjugation of ADCs. The chapter features information on headquarters, size of the company, types of services offered (antibody manufacturing / HPAPI or cytotoxic manufacturing / linker manufacturing / conjugation / fill-finish), location of manufacturing facilities, year of establishment of company / organization, scale of operation, and additional development services offered for ADCs (proof-of-concept studies / process development and scale-up / analytical development). The chapter also includes a list of various contract manufacturers offering antibody production services along with the information on the location of their headquarters. Further, it provides a list of HPAPI / cytotoxic drug manufacturers along with the information on location of facilities dedicated to the manufacturing of such components.

Chapter 5 features profiles of contract service providers that are either one-stop-shops (offering services from antibody manufacturing to fill/ finish operations) or offer conjugation services at the commercial scale. Each profile provides a brief overview of the company, its financial information, details on ADC manufacturing capabilities, location of facilities, recent developments, and a comprehensive future outlook.

Chapter 6 features a detailed comparative analysis of the ADC contract manufacturers. The companies were compared on the basis of various parameters including company size, year of establishment, number of ADC manufacturing services offered, annual revenues, scale of operation, number of ADC development services offered and number of facilities for conjugation services. The results of this analysis were used to highlight the features of the most competent companies working in this domain.

Chapter 7 highlights the investments made by CMOs to expand or set up new facilities in order to support their ongoing operations. For each such instance, we have provided information on month / year of the development, type of development, amount invested (if available), focus area (manufacturing, analytical / development and fill / finish), scale of operation (preclinical, clinical and commercial) and location of the facility in which the investment was made.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked between different players in this market. We have also discussed the different partnership models (including research agreements, manufacturing agreements, technology licensing agreements, product development agreements and acquisitions / mergers) and the most common forms of deals / agreements that have been established between 2012-H1 2018. It consists of a schematic representation showcasing the players that have established the maximum number of alliances related to the manufacturing of ADCs. Furthermore, we have provided a world map representation of the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9 features a comprehensive analysis of the overall installed manufacturing / bioconjugation capacity of contract service providers and an estimate of the quantity of ADCs that can be produced per batch. The analysis highlights the distribution of global capacity by size of the company / organization (small-sized, mid-sized and large-sized) and geography (North America, Europe and Asia Pacific).

Chapter 10 provides a comprehensive overview of the market landscape of ADCs that are already approved and those that are under development (clinical and preclinical). This chapter includes information related to their current phase of development (wherever applicable), key target indications, developer company / organization, affiliated technology provider(s) and the type(s) of cytotoxin(s) and linker(s) used.

Chapter 11 features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies, highlighting the competition between contemporary technology platforms.
Chapter 12 features a comprehensive geographical clinical trial analysis of completed, ongoing and planned studies of various ADCs (approved / under development). The analysis provides details related to the different types of payloads and linkers investigated / being investigated across various geographies, based on the number of trials registered, current trial status, phase of development, number of patients enrolled and duration of the (recently initiated) trials (2015 onwards).

Chapter 13 features a comprehensive analysis of the annual demand of ADCs (in grams) taking into account commercial, as well as clinical scale requirements. This was based on the parameters such as target patient population, dosing frequency and dose strength of approved products and clinical stage candidates.

Chapter 14 presents a comprehensive market forecast analysis, highlighting the likely growth of the contract manufacturing market of ADCs, till 2030. The chapter provides likely distribution of the projected future opportunity based on scale of operation (commercial, phase III, phase II and phase I), component / process type (antibody, cytotoxic / linker, conjugation, fill / finish and others), target indications (solid tumors and hematological malignancies), type of payload used (auristatin, calicheamicin (ozogamicin), duocarmycin, DXd (exatecan derivative), maytansinoid, pyrrolobenzodiazepines (talirine, tesirine) and others), type of linker used (succinimidyl 4-(n-maleimidomethyl) cyclohexane-1-carboxylate, valine-citrulline, hydrazone, valine-alanine, n-succinimidyl-4-(2-pyridyldithio) butanoate and others) and geography (North America, Europe, Asia Pacific and rest of the world).

Chapter 15 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of ADC contract manufacturing market, under a comprehensive SWOT framework.

Chapter 16 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 17 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Aldo Braca (Chief Executive Officer, BSP Pharmaceuticals) and Giorgio Salciarini (Technical Business Development Manager, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Christian Bailly (Director of CDMO, Pierre Fabre), Christian Rohlff (Chief Executive Officer & Founder, Oxford BioTherapeutics), Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza), Mark Wright (Site Head, Piramal Healthcare), Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia), Anonymous (Director, Business Development, Leading CMO) and Anonymous (Chief Executive Officer, Leading CMO)

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies and organizations have been mentioned in the report.

1. 3P Biopharmaceuticals
2. AB Sciex
3. AbbVie
4. AbGenomics
5. ABL Bio
6. Abzena
7. ACES Pharma
8. Adar Biotech
9. ADC Biotechnology
10. ADC Therapeutics
11. Advanced BioScience Laboratories
12. Aesica Pharmaceuticals
13. Affinity Life Sciences
14. Agensys
15. Agno Pharma
16. Ajinomoto Althea
17. Alcami
18. Aldevron
19. Alkermes
20. Allozyne
21. Almac
22. Alpha Cancer Technologies
23. Alphora Research
24. Alteogen
25. Amatsigroup
26. Ambrx
27. Amgen
28. AMPAC Fine Chemicals
29. AMRI
30. Angiex
31. Anogen
32. APO-T
33. Aptuit
34. AqueaTether Therapeutics
35. Arabio
36. Arch Pharmalabs
37. Asana BioSciences
38. Ash Stevens
39. Aspyrian Therapeutics
40. Astellas Pharma
41. AstraZeneca
42. Asymchem
43. AURA Biotechnologies
44. AutekBio
45. Avanthera
46. Avid Bioservices
47. Batavia Biosciences
48. Baxter BioPharma Solutions
49. Bayer HealthCare
50. BerGenBio
51. Bharat Serums and Vaccines
52. BIBITEC
53. BINEX
54. BioAgilytix
55. BioConnection
56. Biomatik
57. BioMed Valley Discoveries
58. Biosynergy
59. Bio-Synthesis
60. BioTechLogic
61. BioTechnique
62. Biotechpharma
63. Biotecnol
64. Biotest
65. BioVectra
66. Biovian
67. BlinkBio
68. Bliss Biopharmaceutical
69. Boehringer Ingelheim BioXcellence
70. Bristol-Myers Squibb
71. Bryllan
72. BSP Pharmaceuticals
73. Cambrex
74. Cambridge Major Laboratories
75. Capsugel
76. CARBOGEN AMCIS
77. Catalent Pharma Solutions
78. Cedarburg Pharmaceuticals
79. Celgene
80. Cell Culture Company
81. Cell Essentials
82. Cellerant Therapeutics
83. CellMosaic
84. Celltrion
85. Celon Laboratories
86. Celonic
87. Centrose
88. Cerbios-Pharma
89. Charles River Laboratories
90. ChemCon
91. ChemPartner
92. ChemSun Pharmaceutical
93. Chiome Bioscience
94. Chugai Pharmaceutical
95. CinnaGen
96. CMC Biologics
97. Cobra Biologics
98. Coldstream Laboratories
99. Compugen
100. Concortis Biotherapeutics
101. Cook Pharmica
102. CordenPharma
103. Creative Biolabs
104. Crystal Pharma
105. Custom Pharma Services
106. CytomX Therapeutics
107. Cytovance Biologics
108. Daiichi Sankyo
109. Dalton Pharma Services
110. Debiopharm
111. DM Bio
112. Dorizoe Lifesciences
113. Dottikon Exclusive Synthesis
114. DSM Pharmaceuticals
115. EirGen Pharma
116. EirGenix
117. Eli Lilly
118. Emergent BioSolutions
119. Esperance Pharmaceuticals
120. ETH Zurich
121. EuBiologics
122. Evonik
123. Excella
124. Farmabios
125. FineTech Pharmaceuticals
126. Formation Biologics
127. Formex
128. Formosa Laboratories
129. For‐Robin
130. Fortis Therapeutics
131. FOSUN Pharma
132. FUJIFILM Diosynth Biotechnologies
133. Fusion Antibodies
134. Gala Biotech
135. GE Healthcare
136. GEA Pharma Systems
137. Genentech
138. Genmab
139. Genzyme
140. Glenmark Pharmaceuticals
141. Glycotope Biotechnology
142. Glythera
143. Goodwin Biotechnology
144. GP Pharm
145. Grand River Aseptic Manufacturing
146. Green Cross
147. Groningen Research Institute of Pharmacy
148. GSK
149. GTP Technology
150. HALIX
151. Halozyme
152. Hangzhou DAC Biotech
153. Haupt Pharma
154. Heidelberg Pharma
155. Helsinn Advanced Synthesis
156. Heraeus Deutschland
157. Hetero
158. Hong Kong Institute of Biotechnology
159. ICROM
160. Idifarma
161. IDT Australia
162. IDT Biologika
163. Igenica Biotherapeutics
164. ImmunoGen
165. Immunomedics
166. Indena
167. Innate Pharma
168. Inno Biologics
169. Innovation Center for Immune Therapy, Tsinghua University
170. Intas Pharmaceuticals
171. Integrity Bio
172. Intellect Neurosciences
173. IRIX Pharmaceuticals
174. JHL Biotech
175. Johns Hopkins University
176. Johnson Matthey
177. Kamat Pharmatech
178. KBI Biopharma
179. Kemwell Biopharma
180. Kyongbo Pharmaceutical
181. Kyowa Hakko Kirin
182. Labochim
183. LAMPIRE Biological Laboratories
184. LegoChem Biosciences
185. Leica Biosystems
186. Levena Biopharma
187. LFB Biomanufacturing
188. LinXis
189. Lonza
190. MAB Discovery
191. MabPlex
192. MabVax Therapeutics
193. MacroGenics
194. Maine Biotechnology Services
195. MassBiologics
196. Medichem
197. MedImmune
198. Meditope Biosciences
199. Medix Biochemica
200. Menarini Group
201. Merck (SAFC)
202. Meridian Life Science
203. Merrimack Pharmaceuticals
204. Mersana Therapeutics
205. Metrics Contract Services
206. Millennium Pharmaceuticals
207. MINAKEM High Potent
208. Mitsubishi Tanabe Pharma
209. Molecular and Cellular Therapeutics, University of Minnesota
210. Morphotek
211. MuseChem
212. Mycenax Biotech
213. NanoValent Pharmaceuticals
214. National Cancer Institute
215. National Research Council Canada
216. NBE Therapeutics
217. NerPharma
218. Nitto Avecia Pharma Services
219. Nordic Nanovector
220. Laboratorios Normon
221. Nova Laboratories
222. Novartis
223. Novasep
224. OBI Pharma
225. OctoPlus
226. Olon
227. OmniChem
228. Oncotec Pharma Produktion
229. Hospira One2One
230. OsoBio
231. Oxford BioTherapeutics
232. Panacea Biotec
233. Paragon Bioservices
234. Particle Sciences
235. Patheon
236. Penn Pharma
237. Pfanstiehl
238. Pfizer
239. Pharmaceutics International
240. PharmaMar
241. Pharmatek
242. Pharmedartis
243. Philochem
244. Philogen
245. Pierre Fabre
246. Piramal Pharma Solutions
247. Polymun Scientific
248. PrasFarma
249. Praxis Pharmaceutical
250. Precision Antibody
251. PREMAS Biotech
252. ProBioGen
253. Procos
254. ProJect Pharmaceutics
255. ProMab Biotechnologies
256. PX'Therapeutics
257. Quotient Sciences
258. Recipharm
259. Redwood Bioscience
260. Regeneron Pharmaceuticals
261. Regis Technologies
262. Reliance Life Sciences
263. RemeGen
264. Rentschler Biopharma
265. Research Corporation Technologies
266. Richter-Helm BioLogics
267. Roche
268. Rottendorf Pharma
269. Saltigo
270. Samsung Medical Center
271. Sandoz
272. Sanofi
273. Sartorius Stedim Biotech
274. ScinoPharm
275. Seasun Biomaterials
276. Seattle Genetics
277. Shenogen
278. Siegfried
279. Sorrento Therapeutics
280. Spirogen
281. STA Pharmaceutical
282. Stason Pharmaceuticals
283. Stemcentrx
284. Sutro Biopharma
285. Symbiosis Pharmaceutical Services
286. Symphogen
287. Synaffix
288. Syndivia
289. Syngene
290. Syntagon
291. Synthon
292. Synthorx
293. Takara Bio
294. Takeda Oncology
295. TAPI
296. TBD-Biodiscovery
297. Telix Pharmaceuticals
298. The Chemistry Research Solution
299. The Scripps Research Institute
300. Theranyx
301. Therapure Biopharma
302. Thermo Fisher Scientific
303. Toyobo Biologics
304. Transporin
305. TranXenoGen
306. Triphase Accelerator
307. Tube Pharma
308. Uman Pharma
309. University of Bonn
310. University of California
311. University of Georgia
312. UPM Pharmaceuticals
313. Uquifa
314. Vaccinex
315. Vetter Pharma
316. Vista Biologicals
317. Visterra
318. VUAB Pharma
319. Waisman Biomanufacturing
320. Weill Cornell Medicine
321. Wolfe Laboratories
322. WuXi Biologics
323. Xintela
324. Yale School of Medicine
325. Zymeworks


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Essential Components of ADCs
3.2.1. Antibody
3.2.2. Cytotoxin
3.2.3. Linker
3.3. ADC Manufacturing
3.3.1. Key Steps
3.3.2. Technical Challenges
3.3.3. Growing Trend of Contract Manufacturing
3.4. Challenges Associated with Supply Chain and Method Transfer
3.4.1. Growing Demand for One Stop Shops and Integrated Service Providers
3.5. Selecting a CMO Partner
4. ADC CONTRACT MANUFACTURERS: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. ADC Contract Manufacturers: Overall Market Landscape
4.2.1. Distribution by Location of Headquarters
4.2.2. Distribution by Year of Establishment
4.2.3. Distribution by Company Size
4.2.4. Distribution by Service(s) Offered
4.2.5. Distribution by Location of Manufacturing Facility
4.2.6. Distribution by Scale of Operation
4.2.7. Distribution by Other ADC Services Offered
4.3. Antibody Manufacturing Service Providers
4.4. HPAPI / Cytotoxic Drug Manufacturing Service Providers
5. COMPANY PROFILES
5.1. Chapter Overview
5.2. Abzena
5.2.1. Company Overview and Financial Information
5.2.2. ADC Offerings
5.2.3. Manufacturing Facilities
5.2.4. Recent Developments
5.2.5. Future Outlook
5.3. Ajinomoto Althea
5.3.1. Company Overview and Financial Information
5.3.2. ADC Offerings
5.3.3. Manufacturing Facilities
5.3.4. Recent Developments
5.3.5. Future Outlook
5.4. BSP Pharmaceuticals
5.4.1. Company Overview
5.4.2. ADC Offerings
5.4.3. Manufacturing Facilities
5.4.4. Recent Developments
5.4.5. Future Outlook
5.5. CARBOGEN AMCIS
5.5.1. Company Overview and Financial Information
5.5.2. ADC Offerings
5.5.3. Manufacturing Facilities
5.5.4. Recent Developments
5.5.5. Future Outlook
5.6. Catalent Pharma Solutions
5.6.1. Company Overview and Financial Information
5.6.2. ADC Offerings
5.6.3. Manufacturing Facilities
5.6.4. Recent Developments
5.6.5. Future Outlook
5.7. Cerbios-Pharma
5.7.1. Company Overview and Financial Information
5.7.2. ADC Offerings
5.7.3. Manufacturing Facilities
5.7.4. Recent Developments
5.7.5. Future Outlook
5.8. Creative Biolabs
5.8.1. Company Overview
5.8.2. ADC Offerings
5.8.3. Manufacturing Facilities
5.8.4. Recent Developments
5.8.5. Future Outlook
5.9. Goodwin Biotechnology
5.9.1. Company Overview
5.9.2. ADC Offerings
5.9.3. Manufacturing Facilities
5.9.4. Recent Developments
5.9.5. Future Outlook
5.10. Levena Biopharma
5.10.1. Company Overview
5.10.2. ADC Offerings
5.10.3. Manufacturing Facilities
5.10.4. Recent Developments
5.10.5. Future Outlook
5.11. Lonza
5.11.1. Company Overview and Financial Information
5.11.2. ADC Offerings
5.11.3. Manufacturing Facilities
5.11.4. Recent Developments
5.11.5. Future Outlook
5.12. MabPlex
5.12.1. Company Overview
5.12.2. ADC Offerings
5.12.3. Manufacturing Facilities
5.12.4. Recent Developments
5.12.5. Future Outlook
5.13. Merck (SAFC)
5.13.1. Company Overview and Financial Information
5.13.2. ADC Offerings
5.13.3. Manufacturing Facilities
5.13.4. Recent Developments
5.13.5. Future Outlook
5.14. Novasep
5.14.1. Company Overview and Financial Information
5.14.2. ADC Offerings
5.14.3. Manufacturing Facilities
5.14.4. Recent Developments
5.14.5. Future Outlook
5.15. Pierre Fabre
5.15.1. Company Overview and Financial Information
5.15.2. ADC Offerings
5.15.3. Manufacturing Facilities
5.15.4. Recent Developments
5.15.5. Future Outlook
5.16. Piramal Pharma Solutions
5.16.1. Company Overview and Financial Information
5.16.2. ADC Offerings
5.16.3. Manufacturing Facilities
5.16.4. Recent Developments
5.16.5. Future Outlook
5.17. Syngene
5.17.1. Company Overview and Financial Information
5.17.2. ADC Offerings
5.17.3. Manufacturing Facilities
5.17.4. Recent Developments
5.17.5. Future Outlook
5.18. WuXi Biologics
5.18.1. Company Overview and Financial Information
5.18.2. ADC Offerings
5.18.3. Manufacturing Facilities
5.18.4. Recent Developments
5.18.5. Future Outlook
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.2.1. Assumptions and Parameters Evaluated
6.3. Affiliated Insights
6.3.1. Spider Web Competitive Analysis: Abzena
6.3.2. Spider Web Competitive Analysis: Cambrex
6.3.3. Spider Web Competitive Analysis: Cerbios-Pharma
6.3.4. Spider Web Competitive Analysis: Merck (SAFC)
6.3.5. Spider Web Competitive Analysis: Novasep
6.3.6. Spider Web Competitive Analysis: Pierre Fabre
6.3.7. Spider Web Competitive Analysis: Piramal Pharma Solutions
6.3.8. Spider Web Competitive Analysis: WuXi Biologics
7. ADC CONTRACT MANUFACTURERS: FACILITY EXPANSIONS
7.1. Chapter Overview
7.2. ADC Contract Manufacturers: Recent Facility Expansions
7.2.1. Analysis by Year of Expansion
7.2.2. Analysis by Type of Expansion
7.2.3. Analysis by Type of Service Offered
7.2.4. Analysis by Type of Service and Year of Expansion
7.2.5. Analysis by Scale of Operation
7.2.6. Analysis by Location of Facility
7.2.7. Analysis by Scale of Operation and Location of Facility
7.2.8. Analysis by Key Players and Type of Expansion
8. ADC CONTRACT MANUFACTURERS: RECENT PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADC Contract Manufacturers: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Key Players by Number of Partnerships
8.3.4. Regional Analysis
8.3.4.1. Most Active Players
8.3.4.2. Intercontinental and Intracontinental Agreements
9. ADC MANUFACTURING: CAPACITY ANALYSIS
9.1. Chapter Overview
9.2. Key Assumptions and Methodology
9.3. ADC Manufacturing: Overall Installed Global Capacity
9.3.1. Distribution by Size of Manufacturers
9.3.2. Distribution by Key Players
9.3.3. Distribution by Headquarters of Manufacturers
9.3.4. Distribution by Location of Manufacturing Facilities
9.3.4.1 By Country
9.3.4.2. By Continent
10. ADC THERAPEUTICS: MARKET OVERVIEW
10.1. Chapter Overview
10.2. ADC Therapeutics: Clinical Pipeline
10.2.1. Distribution by Phase of Development
10.2.2. Distribution by Indication
10.2.3. Distribution by Linker Type
10.2.4. Distribution by Payload Type
10.2.5. Distribution of Technology Providers by Number of Molecules
10.3. ADC Therapeutics: Preclinical / Discovery Pipeline
10.3.1. Distribution of Leading Players by Number of Molecules
11. ADC CONJUGATION TECHNOLOGY PLATFORMS
11.1. Chapter Overview
11.2. First Generation ADC Technologies
11.3. Second Generation ADC Technologies
11.3.1. Cysteine and Selenocysteine Engineering
11.3.2. Unnatural Amino Acid Engineering
11.3.3. Amino-Terminal Serine Engineering
11.4. Third Generation ADC Technologies
11.4.1. Enzyme-Assisted Ligation Approaches
11.4.2. Glycan Remodeling Approaches
11.4.3. Ligation at Fab Nucleotide-Binding Site
11.4.4. Cysteine Rebridging
11.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
11.5. Evolutionary Analysis
12. GEOGRAPHICAL CLINICAL TRIALS ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. ADC Therapeutics: Overall Clinical Trial Analysis
12.3.1. Analysis by Trial Registration Year
12.3.2. Geographical Analysis by Number of Clinical Trials
12.3.3. Geographical Analysis by Enrolled Patient Population
12.4. ADC Therapeutics: Clinical Trial Analysis by Payload Type
12.4.1. Auristatin based Molecules
12.4.1.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.1.2. Geographical Analysis by Enrolled Patient Population
12.4.1.3. Analysis by Duration of Clinical Trials
12.4.2. Maytansinoid based Molecules
12.4.2.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.2.2. Geographical Analysis by Enrolled Patient Population
12.4.2.3. Analysis by Duration of Clinical Trials
12.4.3. Calicheamicin based Molecules
12.4.3.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.3.2. Geographical Analysis by Enrolled Patient Population
12.4.3.3. Analysis by Duration of Clinical Trials
12.4.4. PBDs (talirine, tesirine) based Molecules
12.4.4.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.4.2. Geographical Analysis by Enrolled Patient Population
12.4.4.3. Analysis by Duration of Clinical Trials
12.4.5. Duocarmycin based Molecules
12.4.5.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.5.2. Geographical Analysis by Enrolled Patient Population
12.4.5.3. Analysis by Duration of Clinical Trials
12.4.6. DXd (exatecan Derivative) based Molecules
12.4.6.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.6.2. Geographical Analysis by Enrolled Patient Population
12.4.6.3. Analysis by Duration of Clinical Trials
12.4.7. Molecules having Other Types of Payloads
12.4.7.1. Geographical Analysis by Trial Phase and Recruitment Status
12.4.7.2. Geographical Analysis by Enrolled Patient Population
12.4.7.3. Analysis by Duration of Clinical Trials
12.5. ADC Therapeutics: Clinical Trial Analysis by Linker Type
12.5.1. VC based Molecules
12.5.1.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.1.2. Geographical Analysis by Enrolled Patient Population
12.5.1.3. Analysis by Duration of Clinical Trials
12.5.2. Hydrazone Linker based Molecules
12.5.2.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.2.2. Geographical Analysis by Enrolled Patient Population
12.5.2.3. Analysis by Duration of Clinical Trials
12.5.3. SMCC based Molecules
12.5.3.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.3.2. Geographical Analysis by Enrolled Patient Population
12.5.3.3. Analysis by Duration of Clinical Trials
12.5.4. VA based Molecules
12.5.4.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.4.2. Geographical Analysis by Enrolled Patient Population
12.5.4.3. Analysis by Duration of Clinical Trials
12.5.5. SPDB based Molecules
12.5.5.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.5.2. Geographical Analysis by Enrolled Patient Population
12.5.5.3. Analysis by Duration of Clinical Trials
12.5.6. Molecules having Other Types of Linkers
12.5.6.1. Geographical Analysis by Trial Phase and Recruitment Status
12.5.6.2. Geographical Analysis by Enrolled Patient Population
12.5.6.3. Analysis by Duration of Clinical Trials
13. ADC THERAPEUTICS: DEMAND ANALYSIS
13.1. Chapter Overview
13.2. Key Assumptions and Methodology
13.3. ADC Therapeutics: Overall Annual Demand
13.3.1. ADC Therapeutics: Annual Commercial Demand
13.3.1.1. Distribution by Payload Type
13.3.1.2. Distribution by Linker Type
13.3.1.3. Distribution by Target Cancer Type
13.3.2. ADC Therapeutics: Annual Clinical Demand
13.3.2.1. Distribution by Phase of Development
13.3.2.2. Distribution by Payload Type
13.3.2.3. Distribution by Linker Type
13.3.2.4. Distribution by Target Cancer Type
13.3.2.5. Distribution by Region
13.4. ADC Therapeutics: Demand and Supply Analysis
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Overall ADC Therapeutics Market, 2018-2030
14.4. Input Data and Key Assumptions
14.5. Overall ADC Contract Manufacturing Market, 2018-2030
14.5.1. ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type
14.5.2. ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation
14.6. ADC Contract Manufacturing Market for Commercial Products, 2018-2030
14.6.1. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type
14.6.2. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type
14.6.3. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type
14.6.4. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Target Cancer Type
14.6.5. ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region
14.7. ADC Contract Manufacturing Market for Clinical Products, 2018-2030
14.7.1. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Component / Process Type
14.7.2. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type
14.7.3. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type
14.7.4. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Target Cancer Type
14.7.5. ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region
15. SWOT ANALYSIS
15.1. Chapter Overview
15.1.1. Strengths
15.1.2. Weaknesses
15.1.3. Opportunities
15.1.4. Threats
16. CONCLUSION
16.1. Given the Growing Pipeline of ADC Therapeutics and Associated Manufacturing Challenges, Outsourcing is Considered to be a Viable Business Strategy in this Domain
16.2. Current Market Landscape is Relatively Niche with a Limited Number of Companies Offering End-To-End Services and a Few Players Providing Services at Commercial Scale
16.3. To Keep Pace with the Growing Demand for ADC Therapeutics, Many Contract Manufacturers Have Made Investments or Entered Into Strategic Alliances to Expand Existing Capabilities
16.4. Several Clinical Trials are being Conducted to Evaluate ADC Therapeutics Worldwide, the Majority of Such Studies are Centered in the US
16.5. Owing to the Presence of Several Small Companies and Start-Ups, the Trend of Outsourcing Such Operations is Likely to Flourish in the Coming Years
16.6. The Installed Capacity is Sufficient to Meet the Current Annual Demand; However, as The Demand Rises, CMOs will be Required to Invest in Installing Incremental Capacity
17. INTERVIEW TRANSCRIPTS
17.1. Chapter Overview
17.2. Aldo Braca, Chief Executive Officer and Giorgio Salciarini, Technical Business Development Manager, BSP Pharmaceuticals
17.3. Anthony DeBoer, Director, Business Development, Synaffix
17.4. Christian Bailly, Director of CDMO, Pierre Fabre
17.5. Christian Rohlff, Chief Executive Officer & Founder, Oxford BioTherapeutics
17.6. Jennifer L. Mitcham, Director, Business Development and Stacy McDonald, Group Product Manager, Catalent Pharma Solutions
17.7. John Burt, Chief Executive Officer, Abzena
17.8. Laurent Ducry, Head of Bioconjugates Commercial Development, Lonza
17.9. Mark Wright, Site Head, Piramal Healthcare
17.10. Sasha Koniev, Chief Executive Officer & Co-Founder, Syndivia
17.11. Anonymous, Director, Business Development, Leading CMO
17.12. Anonymous, Chief Executive Officer, Leading CMO
18. APPENDIX 1: TABULATED DATA
19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Components of an ADC
Figure 3.2 ADC Manufacturing Steps
Figure 4.1 ADC Contract Manufacturers: Distribution by Location of Headquarters
Figure 4.2 ADC Contract Manufacturers: Distribution by Year of Establishment
Figure 4.3 ADC Contract Manufacturers: Distribution by Company Size
Figure 4.4 ADC Contract Manufacturers: Distribution by Services Offered
Figure 4.5 ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
Figure 4.6 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 4.7 ADC Contract Manufacturers: Distribution by Scale of Operation
Figure 4.8 ADC Contract Manufacturers: Distribution based on Other Services Offered
Figure 6.1 Company Competitiveness Analysis: Methodology
Figure 6.2 Company Competitiveness Analysis: Dot-Plot Representation
Figure 6.3 Spider-Web Competitive Analysis: Abzena
Figure 6.4 Spider-Web Competitive Analysis: Cambrex
Figure 6.5 Spider-Web Competitive Analysis: Competitive Cerbios-Pharma
Figure 6.6 Spider-Web Competitive Analysis: Merck (SAFC)
Figure 6.7 Spider-Web Competitive Analysis: Novasep
Figure 6.8 Spider-Web Competitive Analysis: Pierre Fabre
Figure 6.9 Spider-Web Competitive Analysis: Piramal Pharma Solutions
Figure 6.10 Spider-Web Competitive Analysis: WuXi Biologics
Figure 7.1 ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
Figure 7.2 ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
Figure 7.3 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service
Figure 7.4 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
Figure 7.5 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
Figure 7.6 ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
Figure 7.7 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
Figure 7.8 ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
Figure 8.1 ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
Figure 8.2 ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
Figure 8.3 ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
Figure 8.4 ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
Figure 8.5 ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
Figure 9.1 Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
Figure 9.2 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Figure 9.3 Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
Figure 9.4 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Country)
Figure 9.5 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Continent)
Figure 10.1 ADCs Clinical Pipeline: Distribution by Phase of Development
Figure 10.2 ADCs Clinical Pipeline: Distribution by Indication
Figure 10.3 ADCs Clinical Pipeline: Distribution by Type of Linker
Figure 10.4 ADCs Clinical Pipeline: Distribution by Type of Warhead
Figure 10.5 ADCs Clinical Pipeline: Distribution by Technology Providers
Figure 10.6 ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
Figure 11.1 ADC Conjugation Platforms: Technological Evolution
Figure 11.2 ADC Conjugation Platforms: Technology Landscape
Figure 12.1 ADC Therapeutics: Year-wise Trend of Clinical Trials
Figure 12.2 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Figure 12.3 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Figure 12.4 Geographical Clinical Trial Analysis: Distribution by Payload Type
Figure 12.5 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.6 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Figure 12.7 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.8 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Figure 12.9 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.10 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Figure 12.11 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.12 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Enrolled Patient Population
Figure 12.13 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.14 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Enrolled Patient Population
Figure 12.15 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.16 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Enrolled Patient Population
Figure 12.17 Geographical Clinical Trial Analysis (Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
Figure 12.18 Geographical Clinical Trial Analysis (Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
Figure 12.19 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Figure 12.20 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.21 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Figure 12.22 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.23 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Figure 12.24 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.25 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Figure 12.26 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.27 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.28 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
Figure 12.29 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Figure 12.30 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
Figure 12.31 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
Figure 13.1 ADC Therapeutics: Overall Annual Demand, 2018-2030 (in kgs)
Figure 13.2 ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Production, 2018-2030 (in kgs)
Figure 13.3 ADC Therapeutics: Overall Annual Commercial Demand, 2018-2030 (in kgs)
Figure 13.4 Annual Commercial Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Figure 13.5 Annual Commercial Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Figure 13.6 Annual Commercial Demand: Distribution by Cancer Type, 2018-2030 (in kgs)
Figure 13.7 ADC Therapeutics: Overall Annual Clinical Demand, 2018-2030 (in kgs)
Figure 13.8 Annual Clinical Demand: Distribution by Phase of Development, 2018-2030 (in kgs)
Figure 13.9 Annual Clinical Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Figure 13.10 Annual Clinical Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Figure 13.11 Annual Clinical Demand: Distribution by Cancer Type, 2018-2030 (in kgs)
Figure 13.12 Annual Clinical Demand: Distribution by Region, 2018-2030 (in kgs)
Figure 13.13 ADC Therapeutics: Demand and Supply Scenario, 2018 - 2030
Figure 14.1 Overall ADC Therapeutics Market, 2018-2030 (USD Billion)
Figure 14.2 ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
Figure 14.3 ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type (USD Million)
Figure 14.4 ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation (USD Million)
Figure 14.5 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type of ADC (USD Million)
Figure 14.6 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type (USD Million)
Figure 14.7 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type (USD Million)
Figure 14.8 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Target Cancer Type (USD Million)
Figure 14.9 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region (USD Million)
Figure 14.10 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Component / Process Type (USD Million)
Figure 14.11 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type (USD Million)
Figure 14.12 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type (USD Million)
Figure 14.13 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Target Cancer Type (USD Million)
Figure 14.14 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Continent (USD Million)
Figure 14.15 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Countries (USD Million)
Figure 15.1 SWOT Analysis: Harvey Ball Analysis
Figure 16.1 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2018, 2025 and 2030 (USD Billion)
LIST OF TABLES
Table 3.1 Commonly used Cytotoxins for ADC Therapeutics
Table 3.2 OEL Bands, Safebridge Consultants
Table 4.1 ADC Contract Manufacturers: List of Service Providers
Table 4.2 ADC Contract Manufacturers: Services Offered
Table 4.3 ADC Contract Manufacturers: Details on Manufacturing Facilities
Table 4.4 ADC Contract Manufacturers: Details on Scale of Production and Capacity
Table 4.5 ADC Contract Manufacturers: Details on Other Services Offered
Table 4.6 ADC Contract Manufacturers: List of Antibody Manufacturing Service Providers
Table 4.7 ADC Contract Manufacturers: List of HPAPI and Cytotoxic Drug Manufacturing Service Providers
Table 5.1 Abzena: Company Overview and Financial Information
Table 5.2 Abzena: ADC Related Offerings
Table 5.3 Abzena: Manufacturing Facilities Information
Table 5.4 Abzena: Recent Developments
Table 5.5 Abzena: Future Outlook
Table 5.6 Ajinomoto Althea: Company Overview and Financial Information
Table 5.7 Ajinomoto Althea: ADC Related Offerings
Table 5.8 Ajinomoto Althea: Manufacturing Facilities Information
Table 5.9 Ajinomoto Althea: Recent Developments
Table 5.10 Ajinomoto Althea: Future Outlook
Table 5.11 BSP Pharmaceuticals: Company Overview
Table 5.12 BSP Pharmaceuticals: ADC Related Offerings
Table 5.13 BSP Pharmaceuticals: Manufacturing Facilities Information
Table 5.14 BSP Pharmaceuticals: Recent Developments
Table 5.15 BSP Pharmaceuticals: Future Outlook
Table 5.16 CARBOGEN AMCIS: Company Overview and Financial Information
Table 5.17 CARBOGEN AMCIS: ADC Related Offerings
Table 5.18 CARBOGEN AMCIS: Manufacturing Facilities Information
Table 5.19 CARBOGEN AMCIS: Recent Developments
Table 5.20 Catalent Pharma Solutions: Company Overview and Financial Information
Table 5.21 Catalent Pharma Solutions: ADC Related Offerings
Table 5.22 Catalent Pharma Solutions: Manufacturing Facilities Information
Table 5.23 Catalent Pharma Solutions: Recent Developments
Table 5.24 Catalent Pharma Solutions: Future Outlook
Table 5.25 Cerbios-Pharma: Company Overview and Financial Information
Table 5.26 Cerbios-Pharma: ADC Related Offerings
Table 5.27 Cerbios-Pharma: Manufacturing Facilities Information
Table 5.28 Cerbios-Pharma: Recent Developments
Table 5.29 Cerbios-Pharma: Future Outlook
Table 5.30 Creative Biolabs: Company Overview
Table 5.31 Creative Biolabs: ADC Related Offerings
Table 5.32 Creative Biolabs: Manufacturing Facilities Information
Table 5.33 Creative Biolabs: Recent Developments
Table 5.34 Creative Biolabs: Future Outlook
Table 5.35 Goodwin Biotechnology: Company Overview
Table 5.36 Goodwin Biotechnology: ADC Related Offerings
Table 5.37 Goodwin Biotechnology: Manufacturing Facilities Information
Table 5.38 Goodwin Biotechnology: Recent Developments
Table 5.39 Goodwin Biotechnology: Future Outlook
Table 5.40 Levena Biopharma: Company Overview
Table 5.41 Levena Biopharma: ADC Related Offerings
Table 5.42 Levena Biopharma: Manufacturing Facilities Information
Table 5.43 Levena Biopharma: Recent Developments
Table 5.44 Levena Biopharma: Future Outlook
Table 5.45 Lonza: Company Overview and Financial Information
Table 5.46 Lonza: ADC Related Offerings
Table 5.47 Lonza: Manufacturing Facilities Information
Table 5.48 Lonza: Recent Developments
Table 5.49 Lonza: Future Outlook
Table 5.50 MabPlex: Company Overview
Table 5.51 MabPlex: ADC Related Offerings
Table 5.52 MabPlex: Manufacturing Facilities Information
Table 5.53 MabPlex: Recent Developments
Table 5.54 MabPlex: Future Outlook
Table 5.55 Merck (SAFC): Company Overview and Financial Information
Table 5.56 Merck (SAFC): ADC Related Offerings
Table 5.57 Merck (SAFC): Manufacturing Facilities Information
Table 5.58 Merck (SAFC): Recent Developments
Table 5.59 Merck (SAFC): Future Outlook
Table 5.60 Novasep: Company Overview and Financial Information
Table 5.61 Novasep: ADC Related Offerings
Table 5.62 Novasep: Manufacturing Facilities Information
Table 5.63 Novasep: Recent Developments
Table 5.64 Novasep: Future Outlook
Table 5.65 Pierre Fabre: Company Overview and Financial Information
Table 5.66 Pierre Fabre: ADC Related Offerings
Table 5.67 Pierre Fabre: Manufacturing Facilities Information
Table 5.68 Pierre Fabre: Recent Developments
Table 5.69 Pierre Fabre: Future Outlook
Table 5.70 Piramal Pharma Solutions: Company Overview and Financial Information
Table 5.71 Piramal Pharma Solutions: ADC Related Offerings
Table 5.72 Piramal Pharma Solutions: Manufacturing Facilities Information
Table 5.73 Piramal Pharma Solutions: Recent Developments
Table 5.74 Piramal Pharma Solutions: Future Outlook
Table 5.75 Syngene: Company Overview and Financial Information
Table 5.76 Syngene: ADC Related Offerings
Table 5.77 Syngene: Information on Manufacturing Facilities
Table 5.78 Syngene: Recent Developments
Table 5.79 Syngene: Future Outlook
Table 5.80 WuXi Biologics: Company Overview and Financial Information
Table 5.81 WuXi Biologics: ADC Related Offerings
Table 5.82 WuXi Biologics: Manufacturing Facilities Information
Table 5.83 WuXi Biologics: Recent Developments
Table 5.84 WuXi Biologics: Future Outlook
Table 6.1 Company Competitiveness Analysis: Shortlisted Players
Table 6.2 Company Competitiveness Analysis: Spiderweb Parameters for Shortlisted Players
Table 7.1 ADC Contract Manufacturers: Recent Facility Expansions
Table 8.1 ADC Contract Manufacturing: Partnerships and Collaborations, 2012-2018
Table 8.2 ADC Contract Manufacturing Partnerships: Most Active Players
Table 9.1 ADC Manufacturing Installed Global Capacity: Sample Data Set
Table 9.2 ADC Manufacturing Installed Global Capacity: Sample Data Set (Average Capacity)
Table 9.3 ADC Manufacturing Installed Global Capacity in Grams: Total Capacity by Size of Manufacturers
Table 10.1 ADC Therapeutics: Clinical Pipeline
Table 10.2 ADC Therapeutics: Clinical Pipeline (Information on Linkers and Payloads)
Table 10.3 ADC Therapeutics: Preclinical / Discovery Pipeline
Table 11.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
Table 11.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
Table 11.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
Table 11.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 11.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
Table 11.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
Table 11.7 Third Generation ADC Technologies: Cysteine Rebridging
Table 11.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
Table 12.1 Geographical Clinical Trial Analysis (Auristatin Based Molecules): Duration of Trials
Table 12.2 Geographical Clinical Trial Analysis (Maytansinoid Based Molecules): Duration of Trials
Table 12.3 Geographical Clinical Trial Analysis (Calicheamicin Based Molecules): Duration of Trials
Table 12.4 Geographical Clinical Trial Analysis (PBDs Based Molecules): Duration of Trials
Table 12.5 Geographical Clinical Trial Analysis (Duocarmycin Based Molecules): Duration of Trials
Table 12.6 Geographical Clinical Trial Analysis (DXd Based Molecules): Duration of Trials
Table 12.7 Geographical Clinical Trial Analysis (Other Types of Payload based Molecules): Duration of the Trials
Table 12.8 Geographical Clinical Trial Analysis (VC based Molecules): Duration of the Trials
Table 12.9 Geographical Clinical Trial Analysis (Hydrazone Linker Based Molecules): Duration of Trials
Table 12.10 Geographical Clinical Trial Analysis (SMCC Based Molecules): Duration of Trials
Table 12.11 Geographical Clinical Trial Analysis (VA Based Molecules): Duration of Trials
Table 12.12 Geographical Clinical Trial Analysis (SPDB Based Molecules): Duration of Trials
Table 12.13 Other Types of Linkers based ADC Therapeutics: Duration of the Trials
Table 14.1 Late Stage ADCs: Development Status
Table 14.2 ADC Therapeutics: Outsourcing Activity for Late Stage Molecules
Table 18.1 ADC Contract Manufacturers: Distribution by Location of Headquarters
Table 18.2 ADC Contract Manufacturers: Distribution by Year of Establishment
Table 18.3 ADC Contract Manufacturers: Distribution by Company Size
Table 18.4 ADC Contract Manufacturers: Distribution by Services Offered
Table 18.5 ADC Contract Manufacturers: Distribution by Location of Headquarters and Services Offered
Table 18.6 ADC Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 18.7 ADC Contract Manufacturers: Distribution by Scale of Operation
Table 18.8 ADC Contract Manufacturers: Distribution based on Other Services Offered
Table 18.9 ADC Contract Manufacturers: Facility Expansions, Distribution by Year, 2012-2018
Table 18.10 ADC Contract Manufacturers: Distribution by Type of Recent Facility Expansion
Table 18.11 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service
Table 18.12 ADC Contract Manufacturers: Facility Expansions, Distribution by Type of Service and Year of Expansion
Table 18.13 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation
Table 18.14 ADC Contract Manufacturers: Facility Expansions, Distribution by Location of Facility
Table 18.15 ADC Contract Manufacturers: Facility Expansions, Distribution by Scale of Operation and Location of Facility
Table 18.16 ADC Contract Manufacturers: Facility Expansions, Distribution by Key Players and Type of Expansion
Table 18.17 ADC Contract Manufacturing: Partnerships and Collaborations, Cumulative Trend by Year, 2012-2018
Table 18.18 ADC Contract Manufacturing: Partnerships and Collaborations, Distribution by Type of Partnership
Table 18.19 ADC Contract Manufacturing: Partnerships and Collaborations, Most Active Players
Table 18.20 ADC Contract Manufacturing: Partnerships and Collaborations, Regional Distribution
Table 18.21 ADC Contract Manufacturing: Partnerships and Collaborations, Intercontinental and Intracontinental Distribution
Table 18.22 Overall ADC Installed Manufacturing Capacity: Distribution by Size of Manufacturers
Table 18.23 Overall ADC Installed Manufacturing Capacity: Distribution by Key Players
Table 18.24 Overall ADC Installed Manufacturing Capacity: Distribution by Headquarters of Manufacturers
Table 18.25 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Country)
Table 18.26 Overall ADC Installed Manufacturing Capacity: Distribution by Location of Manufacturing Facilities (by Continent)
Table 18.27 ADCs Clinical Pipeline: Distribution by Phase of Development
Table 18.28 ADCs Clinical Pipeline: Distribution by Indication
Table 18.29 ADCs Clinical Pipeline: Distribution by Type of Linker
Table 18.30 ADCs Clinical Pipeline: Distribution by Type of Warhead
Table 18.31 ADCs Clinical Pipeline: Distribution by Technology Providers
Table 18.32 ADCs Preclinical / Discovery Pipeline: Relative Distribution of Key Technology Providers
Table 18.33 ADC Therapeutics: Year-wise Trend of Clinical Trials
Table 18.34 Geographical Clinical Trial Analysis: Distribution by Number of Trials
Table 18.35 Geographical Clinical Trial Analysis: Distribution by Enrolled Patient Population
Table 18.36 Geographical Clinical Trial Analysis: Distribution by Payload Type
Table 18.37 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.38 Geographical Clinical Trial Analysis (Auristatin based Molecules): Distribution by Enrolled Patient Population
Table 18.39 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.40 Geographical Clinical Trial Analysis (Maytansinoid based Molecules): Distribution by Enrolled Patient Population
Table 18.41 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.42 Geographical Clinical Trial Analysis (Calicheamicin based Molecules): Distribution by Enrolled Patient Population
Table 18.43 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.44 Geographical Clinical Trial Analysis (PBDs based Molecules): Distribution by Enrolled Patient Population
Table 18.45 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.46 Geographical Clinical Trial Analysis (Duocarmycin based Molecules): Distribution by Enrolled Patient Population
Table 18.47 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.48 Geographical Clinical Trial Analysis (DXd based Molecules): Distribution by Enrolled Patient Population
Table 18.49 Geographical Clinical Trial Analysis (Molecules having Other Types of Payloads): Distribution by Trial Phase and Recruitment Status
Table 18.50 Geographical Clinical Trial Analysis (Molecules having Other Types of Payload): Distribution by Enrolled Patient Population
Table 18.51 ADC Therapeutics: Geographical Clinical Trial Distribution by Linker Type
Table 18.52 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.53 Geographical Clinical Trial Analysis (VC based Molecules): Distribution by Enrolled Patient Population
Table 18.54 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.55 Geographical Clinical Trial Analysis (Hydrazone Linker based Molecules): Distribution by Enrolled Patient Population
Table 18.56 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.57 Geographical Clinical Trial Analysis (SMCC based Molecules): Distribution by Enrolled Patient Population
Table 18.58 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.59 Geographical Clinical Trial Analysis (VA based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.60 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Trial Phase and Recruitment Status
Table 18.61 Geographical Clinical Trial Analysis (SPDB based Molecules): Distribution by Enrolled Patient Population
Table 18.62 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Trial Phase and Recruitment Status
Table 18.63 Geographical Clinical Trial Analysis (Molecules having Other Types of Linkers): Distribution by Enrolled Patient Population
Table 18.64 ADC Therapeutics: Overall Annual Demand, 2018-2030 (in kgs)
Table 18.65 ADC Therapeutics: Overall Annual Demand, Distribution by Scale of Operation, 2018-2030 (in kgs)
Table 18.66 ADC Therapeutics: Overall Annual Commercial Demand, 2018-2030 (in kgs)
Table 18.67 Annual Commercial Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Table 18.68 Annual Commercial Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Table 18.69 Annual Commercial Demand: Distribution by Target Cancer Type, 2018-2030 (in kgs)
Table 18.70 ADC Therapeutics: Overall Annual Clinical Demand, 2018-2030 (in kgs)
Table 18.71 Annual Clinical Demand: Distribution by Phase of Development, 2018-2030 (in kgs)
Table 18.72 Annual Clinical Demand: Distribution by Payload Type, 2018-2030 (in kgs)
Table 18.73 Annual Clinical Demand: Distribution by Linker Type, 2018-2030 (in kgs)
Table 18.74 Annual Clinical Demand: Distribution by Target Cancer Type, 2018-2030 (in kgs)
Table 18.75 Annual Clinical Demand: Distribution by Region, 2018-2030 (in kgs)
Table 18.76 Overall ADC Therapeutics Market: Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 18.77 ADC Therapeutics: Relative Cost of Manufacturing by Component / Process Type
Table 18.78 ADC Contract Manufacturing Market, 2018-2030: Distribution by Component / Process Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.79 ADC Contract Manufacturing Market, 2018-2030: Distribution by Scale of Operation (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.80 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Component / Process Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.81 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Payload Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.82 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Linker Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.83 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Target Cancer Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.84 ADC Contract Manufacturing Market for Commercial Products, 2018-2030: Distribution by Region (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.85 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Components of ADC (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.86 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Payload Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.87 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Linker Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.88 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Target Cancer Type (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.89 ADC Contract Manufacturing Market for Clinical Products, 2018-2030: Distribution by Region (USD Million), Conservative, Base and Optimistic Scenarios
Table 18.90 ADC Contract Manufacturing Market: Conservative, Base and Optimistic Scenario, 2018, 2025 and 2030 (USD Billion)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report